Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Malignant Melanoma Clinical Trials

A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (224) clinical trials

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

OBJECTIVES: Primary - Compare the tumor-specific immune response, in terms of the number of gp100-specific cytotoxic T-lymphocytes, T-cell production of interferon gamma, or T-cell proliferation in response to in vitro exposure to gp100 and tumor lysate, in patients with stage III or IV melanoma treated with autologous dendritic cells (DC) ...


Combination of Temozolomide and Sunitinib in Treatment of Patients With Metastatic and Unresectable Malignant Melanoma

The therapy with a combination of a chemotherapeutic agent with a known activity against melanoma (temozolomide) and a new small molecule that inhibits angiogenesis (sunitinib malate) will be tested in this clinical trial. Both agents have been approved for use in humans with different types of malignancies, and the tolerated ...


Melanoma Molecular Profiling Analysis

There is a significant need to develop new and more effective ways to treat melanoma that will decrease patient morbidity and mortality. This protocol intends to collect and process a portion (< 20% of any node) of lymph nodes from melanoma patients undergoing routine surgical SLN resection: the SLN(s) and ...

Phase N/A

Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy

OBJECTIVES: - Develop a predictive model for sentinel lymph node biopsy positivity in patients with melanoma who have undergone sentinel lymph node biopsy. - Develop a survival model for relapse based on sentinel lymph node biopsy positivity. - Assess the genetic determinants in primary melanomas that predict a metastatic phenotype ...

Phase N/A

Effects of Monoclonal Antibody GC1008 in Blood Samples From Patients With Unresectable Locally Advanced or Metastatic Kidney Cancer or Malignant Melanoma Treated on Clinical Trial NCI-06-C-0200

OBJECTIVES: - To determine whether treatment with human anti-TGF-beta monoclonal antibody GC1008 results in a detectable decrease in phospho-Smad2 levels in freshly collected blood samples from patients with unresectable locally advanced or metastatic renal cell carcinoma or malignant melanoma treated on clinical trial NCI-06-C-0200. - To determine whether the decrease ...

Phase N/A

Follow Up Protocol for Subjects Previously Enrolled in NCI Surgery Branch Studies

BACKGROUND: - Patients receiving care at the NIH Clinical Center are required to be enrolled in a clinical protocol - Following participation in a treatment protocol, it may be in the best interest of the patient to continue to be followed at the Clinical Center - The NCI Surgery Branch ...

Phase N/A

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.

This is a multi-center, open label, phase IV study to provide continued supply of pasireotide to patients being treated in a current Novartis-sponsored, Oncology CD&MA study and who are benefiting from treatment with pasireotide. Eligible patients are to be consented and can then continue treatment with pasireotide in this protocol. ...


The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

This is a single-arm, multicenter study of vemurafenib in patients with biopsy-accessible advanced metastatic melanoma. The trial will consist of a screening period, a treatment phase, and one post-study follow-up visit occurring about 30 days after the last dose of drug. Day 1 of the study will be defined as ...


Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma

This is a single arm, multi-center Phase II clinical trial to assess the safety and demonstrate the efficacy of a combined modality approach using radiation therapy after induction and concurrently with systemic administration of vismodegib, which may increase the rates of complete response and sustained local control in patients with ...


Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

Primary Objectives Evaluate the safety and tolerability of the proposed schedule of decitabine and Vemurafenib plus Cobimetinib in the treatment of metastatic melanoma. Assess tumor response rates by RECIST criteria Secondary Objectives To measure the time to progression of patients treated with this combination in comparison to patients treated historically ...